Tg Therapeutics, Inc. (TGTX): who owns it and who trades it
As of Nov 16, 2026, TGTX insiders reported 2 open-market sales worth $438K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Laurence N Charney (Director), with $275K. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling TG Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns TGTX
425 funds and institutions reported TGTX shares worth $6.2B at the end of Q2 2026, about 73% of the company. The largest holder is BlackRock, Inc. with 14.4%.
Funds and institutions (13F) 73%Everyone else 27%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 22.05M | 14.40% | $1.2B | -1% |
| Vanguard Portfolio Management LLC | 7.96M | 5.20% | $438M | -4% |
| State Street Corp | 7.79M | 5.09% | $428M | -10% |
| Vanguard Capital Management LLC | 6.15M | 4.02% | $338M | -7% |
| Geode Capital Management, LLC | 3.64M | 2.38% | $200M | +4% |
| D. E. Shaw & Co., Inc. | 3.40M | 2.22% | $187M | +476% |
| Soleus Capital Management, L.P. | 2.93M | 1.91% | $161M | -27% |
| T. Rowe Price Associates | 2.77M | 1.81% | $152M | +337% |
| Clearbridge Investments, LLC | 2.65M | 1.73% | $146M | -17% |
| Congress Asset Management Co | 2.60M | 1.70% | $143M | +20% |
| Two Sigma Investments, LP | 2.47M | 1.61% | $136M | +60% |
| Goldman Sachs Group Inc | 2.31M | 1.51% | $127M | +1% |
| Pictet Asset Management Holding SA | 1.79M | 1.17% | $98.1M | +2% |
| Jane Street Group, LLC | 1.75M | 1.14% | $96.3M | -14% |
| Nuveen, LLC | 1.63M | 1.06% | $89.3M | +12% |
| Morgan Stanley | 1.60M | 1.05% | $88M | +14% |
| Hood River Capital Management LLC | 1.60M | 1.05% | $87.9M | +2% |
| Northern Trust Corp | 1.54M | 1.00% | $84.4M | +7% |
| Charles Schwab Investment Management Inc | 1.31M | 0.86% | $72.1M | +1% |
| Sixth Street Partners Management Company, L.P. | 1.31M | 0.86% | $72.1M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, TGTX insiders reported $0 of open-market purchases and $438K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Laurence N Charney | Director | Sale | 5,000 | $54.96 | $275K | Form 4 |
| Nov 24, 2025 | Yann Echelard | Director | Sale | 5,000 | $32.57 | $163K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Laurence N Charney | Director | – | $275K | Sep 10, 2026 |
| Yann Echelard | Director | – | $163K | Nov 24, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
TGTX short interest
High short interest. 18.8% of TGTX shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went up 2%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 28.77M TGTX shares were sold short, 18.8% of the shares outstanding, down 2.8% from the report before. At the average daily volume of 1.52M shares, buying them all back would take about 18.9 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 28.77M | 18.79% | -3% | 1.52M | 18.9 |
| Oct 15, 2026 | 29.59M | 19.33% | -3% | 1.56M | 18.9 |
| Sep 30, 2026 | 30.63M | 20.01% | +2% | 2.04M | 15.0 |
| Sep 15, 2026 | 30.15M | 19.70% | +0% | 1.63M | 18.5 |
| Aug 31, 2026 | 30.13M | 19.68% | +0% | 1.90M | 15.9 |
| Aug 14, 2026 | 30.11M | 19.67% | +3% | 2.39M | 12.6 |
| Jul 31, 2026 | 29.32M | 19.15% | -4% | 2.15M | 13.6 |
| Jul 15, 2026 | 30.69M | 20.05% | +2% | 1.99M | 15.4 |
| Jun 30, 2026 | 30.17M | 19.71% | -0% | 3.64M | 8.3 |
| Jun 15, 2026 | 30.21M | 19.73% | +7% | 2.49M | 12.1 |
| May 29, 2026 | 28.18M | 18.41% | +0% | 1.31M | 21.6 |
| May 15, 2026 | 28.11M | 18.36% | +4% | 2.76M | 10.2 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
TG Therapeutics company events
TG Therapeutics filed 9 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Aug 3, 2026ResultsReleased financial results. Filing
- Jun 12, 2026VoteReported shareholder vote results. Filing
- Jun 3, 2026AnnouncementTG Therapeutics, Inc. issued a press release announced positive pharmacokinetic (PK), pharmacodynamic (PD), safety, and tolerability data from its Phase 1 clinical trial evaluating a subcutaneous formulation of ublituximab (the active agent in BRIUMVI®) in patients with relapsing forms of multiple… Filing
- May 27, 2026AnnouncementTG Therapeutics, Inc. issued a press release announcing positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS). Filing
- May 6, 2026ResultsReleased financial results. Filing
- Mar 20, 2026AgreementThe Company entered into the first amendment agreement, dated as of the Closing Date, by and among the Borrower, certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent, which amends the financing agreement, dated as… Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 13, 2026AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
TG Therapeutics financials
Famous investors that hold TGTX
6 of the 50 well-known investors we track reported holding TGTX in their latest 13F filing. The largest position is Ray Dalio's, worth $32.7M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ray Dalio · Bridgewater Associates | Q3 2026 | 586,631 | $32.7M | 0.1% | +36% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 451,269 | $25.2M | 0.0% | +70% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 449,000 | $25M | 0.0% | -34% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 154,278 | $8.6M | 0.0% | -71% |
| Israel Englander · Millennium Management | Q3 2026 | 103,722 | $5.8M | 0.0% | -62% |
| Larry Robbins · Glenview Capital Management | Q3 2026 | 4,800 | $268K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named TGTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 13.8% |
| Oct 27, 2026 | BlackRock, Inc. | 13G/A | 13.8% |
Questions about Tg Therapeutics, Inc. (TGTX) stock
Who owns the most TGTX stock?
The largest reported owner of Tg Therapeutics, Inc. (TGTX) is BlackRock, Inc., with 14.4% of the company. In total, 425 funds and institutions reported holding TGTX at the end of Q2 2026, together about 73% of the shares. See the largest owners.
Are TGTX insiders buying or selling?
In the last 12 months, TGTX insiders reported no open-market purchases and 2 sales worth $438K. The latest trade was on Sep 10, 2026. See every trade.
What is the short interest in TGTX?
As of Oct 30, 2026, 28.77M TGTX shares were sold short, 18.8% of the shares outstanding, down 2.8% from the report before. At the average daily volume of 1.52M shares, buying them all back would take about 18.9 trading days (days to cover). See the history.
Which famous investors hold TGTX?
6 of the 50 well-known investors we track reported TGTX in their latest 13F filing, including Ray Dalio, Steve Cohen, Jim Simons. The largest position is worth $32.7M. See all holders.
Executive pay
TG Therapeutics's chief executive was paid a total of $25.6M for the year ended Dec 31, 2025, up 36% from $18.8M the year before. In the last 12 months, TG Therapeutics's executives and directors bought no stock on the open market and sold $438K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.